Abstract: Hypertension and renal disease are mutually causative. The blood pressure treatment goal of patients with chronic kidney disease (CKD) is more strict than that of the general population, and it is more difficult to reach the target. The emergence of angiotensin receptorneprilysin inhibitor (ARNI) provides a new drug for the hypertension. Current studies have shown that ARNI has stronger antihypertensive efficacy than the five traditional antihypertensive drugs, and can provide better protection for target organs such as heart and kidney. In terms of safety, it is also superior then the single reninangiotensinaldosterone system (RAAS) inhibitor. The clinical application of ARNI in patients with CKD deserves further exploration.